It has been shown to be highly effective in hospitalized COVID-19 patients presenting with hypoxia with oxygen saturation of <92% and elevated markers of systemic inflammation, most notably CRP ≥ 75 mg/L, when administered in addition to dexamethasone [65]. The gene discussed is CRP; the disease is COVID-19.